mAbsolve
Pre-clinicalBuilding on 40 years of innovation Our Technology Building on 40 years of innovation we have developed a novel Fc variant which is comprehensively more silenced than all previous attempts (including LALA, LALAPG, aglycosylated etc). For approximately 50% of antibody and Fc fusion proteins in clinical development, Fc effector function is not a mechanism of
About
Building on 40 years of innovation Our Technology Building on 40 years of innovation we have developed a novel Fc variant which is comprehensively more silenced than all previous attempts (including LALA, LALAPG, aglycosylated etc). For approximately 50% of antibody and Fc fusion proteins in clinical development, Fc effector function is not a mechanism of
Company Info
Contact
Sectors
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile